THRB and metabolic dysfunction-associated steatohepatitis: The first approved thyroid hormone receptor beta (THR-β) agonist, resmetirom (Rezdiffra), is indicated for non-cirrhotic non-alcoholic steatohepatitis (NASH) patients with moderate to advanced liver fibrosis (Brisnovali et al., 2024).